BLOOD PRESSURE MANAGEMENT WITH RAMIPRIL IN DIABETIC NEPHROPATHY (BPMR)
Principal Investigator: Raymond P. Bain, Ph.D.
The Biostatistics Center was the biostatistical coordinating center for the Blood Pressure Management with Ramipril in Diabetic Nephropathy; a multi-center clinical trial of moderate versus intensive blood pressure control in diabetics with chronic renal disease. The blood pressure management trial was a randomized clinical trial designed to evaluate the safety and efficacy of two levels of blood pressure control with the angiotensin converting enzyme inhibitor (ACEi) ramipril on renal function changes in participants with overt diabetic nephropathy. Over a one-year period, 17 clinical sites in the US randomized a total of 129 insulin-dependent diabetes mellitus (IDDM) participants who completed follow-up in the trial of Angiotensin Converting Enzyme Inhibition (ACEi) with Captopril in Diabetic Nephropathy Nephropathy. The follow-on participants were randomized to one of two blood pressure control groups: moderate goal (mean arterial pressure of between 100 and 107 mmHg, inclusive) or intensive goal (mean arterial pressure of 92 mmHg or less). Participants were followed for two years with quarterly visits (J. Am. Soc. Nephrol. 1995;5:1775-1781).
Funded by NIH/NIDDK (R01-DK-39826), Hoechst-Roussel Pharmaceuticals Inc and Hoechst Marion Roussel Inc, 1993-1996.)